FDA issues naming guidance
This article was originally published in The Tan Sheet
Executive Summary
A guidance published Feb. 8 outlines what information FDA needs from manufacturers to evaluate proposed proprietary names to ensure the names do not look or sound like other drug names, which could cause medication errors, according to a Federal Register notice. The 1guidance does not include long-awaited best practices for naming, labeling and packaging drugs or details on a pilot program for evaluating proposed proprietary names, according to the notice. FDA's pilot program to reduce drug name confusion offered firms little reason to participate (2"The Tan Sheet" June 30, 2008). The drug name review process does not apply to monograph drugs but to Rx drugs and OTCs approved through new drug applications, abbreviated NDAs and investigational new drugs
You may also be interested in...
FDA’s Proposed Name Review Pilot Offers Little Reason To Participate
A proposed FDA pilot program that would shift the burden for safety review of proprietary drug names from the agency to industry needs to account for key differences between OTC and Rx products and lacks participation incentives, pharmaceutical researchers say
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.